Myelodysplastic syndromes | Aplastic Anemia & MDS International Foundation Return to top.
  1. Education
  2. Research Articles
  3. Myelodysplastic syndromes

Myelodysplastic syndromes

Journal Title: 
J Natl Compr Canc Netw
Primary Author: 
Greenberg PL
Author(s): 
Greenberg PL, Attar E, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, Frankfurt O, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, O'Donnell MR, Shami PJ, Stein BL, Stone RM, Thompson JE, Westervelt P, Wheele
Original Publication Date: 
Monday, July 1, 2013
Full Article on PubMed: 
https://www.ncbi.nlm.nih.gov/pubmed/23847220/

The myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic disorders characterized by cytopenias, dysplasia in one or more myeloid lineages, and the potential for development of acute myeloid leukemia. These disorders primarily affect older adults. The NCCN Clinical Practice Guidelines in Oncology for MDS provide recommendations on the diagnostic evaluation and classification of MDS, risk evaluation according to established prognostic assessment tools (including the new revised International Prognostic Scoring System), treatment options according to risk categories, and management of related anemia.

Bone Marrow Disease(s): 
  • myelodysplastic syndromes (MDS)
Share with addtoany.com.